» Articles » PMID: 21165747

Clinical Practice: the Management of Hyperammonemia

Overview
Journal Eur J Pediatr
Specialty Pediatrics
Date 2010 Dec 18
PMID 21165747
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Hyperammonemia is a life-threatening condition which can affect patients at any age. Elevations of ammonia in plasma indicate its increased production and/or decreased detoxification. The hepatic urea cycle is the main pathway to detoxify ammonia; it can be defective due to an inherited enzyme deficiency or secondary to accumulated toxic metabolites or substrate depletion. Clinical signs and symptoms in hyperammonemia are unspecific but they are mostly neurological. Thus, in any unexplained change in consciousness or in any unexplained encephalopathy, hyperammonemia must be excluded as fast as possible. Any delay in recognition and start of treatment of hyperammonemia may have deleterious consequences for the patient. Treatment largely depends on the underlying cause but is, at least in pediatric patients, mainly aimed at establishing anabolism to avoid endogenous protein breakdown and amino acid imbalances. In addition, pharmacological treatment options exist to improve urea cycle function or to remove nitrogen, but their use depend on the underlying disorder. To improve the prognosis of acute hyperammonemia, an increased awareness of this condition is probably more needed than anything else. Likewise, the immediate start of appropriate therapy is of utmost importance. This review focuses on a better understanding of factors leading to ammonia elevations and on practical aspects related to diagnosis and treatment in order to improve clinical management of hyperammonemia.

Citing Articles

Role of carglumic acid in the long-term management of propionic and methylmalonic acidurias.

Yap S, Gasperini S, Matsumoto S, Feillet F Orphanet J Rare Dis. 2024; 19(1):464.

PMID: 39695809 PMC: 11654332. DOI: 10.1186/s13023-024-03468-4.


Prognostic value of serum ammonia in critical patients with non-hepatic disease: A prospective, observational, multicenter study.

Li Y, Yao Z, Li Y, Yang Z, Li M, Chen Z J Transl Int Med. 2023; 11(4):401-409.

PMID: 38130646 PMC: 10732347. DOI: 10.2478/jtim-2022-0021.


Genetic background and clinical characteristics of infantile hyperammonemia.

Li M, Chen X, Chen H, Hu L, Cao Y, Cheng G Transl Pediatr. 2023; 12(5):882-889.

PMID: 37305718 PMC: 10248927. DOI: 10.21037/tp-22-359.


[Expert consensus on the diagnosis and treatment of neonatal hyperammonemia].

Zhongguo Dang Dai Er Ke Za Zhi. 2023; 25(5):437-447.

PMID: 37272168 PMC: 10247199. DOI: 10.7499/j.issn.1008-8830.2302140.


Hyperammonaemic encephalopathy: a remarkably rare complication after bariatric surgery.

Jhamb S, Sidhu T, Whiting S J Surg Case Rep. 2023; 2023(5):rjad227.

PMID: 37153826 PMC: 10154174. DOI: 10.1093/jscr/rjad227.


References
1.
Cooper A . Role of glutamine in cerebral nitrogen metabolism and ammonia neurotoxicity. Ment Retard Dev Disabil Res Rev. 2002; 7(4):280-6. DOI: 10.1002/mrdd.1039. View

2.
COLOMBO J, Peheim E, Kretschmer R, Dauwalder H, Sidiropoulos D . Plasma ammonia concentrations in newborns and children. Clin Chim Acta. 1984; 138(3):283-91. DOI: 10.1016/0009-8981(84)90135-9. View

3.
Connelly A, Cross J, Gadian D, Hunter J, Kirkham F, Leonard J . Magnetic resonance spectroscopy shows increased brain glutamine in ornithine carbamoyl transferase deficiency. Pediatr Res. 1993; 33(1):77-81. DOI: 10.1203/00006450-199301000-00016. View

4.
Picca S, Dionisi-Vici C, Abeni D, Pastore A, Rizzo C, Orzalesi M . Extracorporeal dialysis in neonatal hyperammonemia: modalities and prognostic indicators. Pediatr Nephrol. 2001; 16(11):862-7. DOI: 10.1007/s004670100702. View

5.
WINDMUELLER H . Glutamine utilization by the small intestine. Adv Enzymol Relat Areas Mol Biol. 1982; 53:201-37. DOI: 10.1002/9780470122983.ch6. View